In LS, particularly among individuals with MLH1, MSH2, or EPCAM mutations, close monitoring for MM, BCC, SCC, and precancerous lesions—beyond rare sebaceous manifestations—may be warranted starting at age 18. This evidence concerns the gene MSH2 and Miyoshi myopathy.